© EQS Newswire
16.12.2025
SOON
LISTED
SIX
Sonova strengthens digital health portfolio with SilentCloud™ acquisition, advancing integrated hearing care
News Preview
Sonova Holding AG
/ Key word(s): Acquisition
Sonova strengthens digital health portfolio with SilentCloud™ acquisition, advancing integrated hearing care
16.12.2025 / 07:00 CET/CEST
Group Media & Investor Release
Stäfa (Switzerland), December 16, 2025 – Sonova, a leading provider of innovative hearing solutions, tod......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.12.2025
SOON
LISTED
SIX
Sonova stärkt ihr digitales Gesundheitsportfolio durch SilentCloud™-Akquisition und treibt integrierte Hörversorgung voran
News Preview
Sonova Holding AG
/ Schlagwort(e): Ankauf
Sonova stärkt ihr digitales Gesundheitsportfolio durch SilentCloud™-Akquisition und treibt integrierte Hörversorgung voran
16.12.2025 / 07:00 CET/CEST
Group Media & Investor Release
Stäfa (Schweiz), 16. Dezember 2025 – Sonova, ein führender Anbieter innovativer Hörlösungen, ......
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2025
NKTR
LISTED
NASDAQ
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
News Preview
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinica...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
15.12.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grant
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 31,500 common s...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
15.12.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST....
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ORY
LISTED
BME
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
News Preview
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS15 December 2025 at 14.30 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
IBAB
LISTED
EURONEXT
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer
News Preview
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – p...
Themefolio
Profiler
Peergroup
© PR Newswire
13.12.2025
SOBI
LISTED
STO
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
News Preview
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectorySTOCKHOLM, Dec. 13, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage...
Themefolio
Profiler
Peergroup
© PR Newswire
13.12.2025
SOBI
LISTED
STO
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
News Preview
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectorySTOCKHOLM, Dec. 13, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
12.12.2025
SOBI
LISTED
STO
Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
News Preview
Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-MPGN treatment for patients 12 and olderSTOCKHOLM, Dec. 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Me...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
SECT_B
LISTED
STO
Sectra's six-month interim report 2025/2026: Growth and increased profitability driven by customer satisfaction
News Preview
LINKÖPING, Sweden, Dec. 12, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) reported high order bookings, increased sales and profitability in the first half of 25/26. High levels of customer satisfaction resulted in new and expanded customer commitments, helping to further strengthen Sectra's m...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
SECT_B
LISTED
STO
Sectra's six-month interim report 2025/2026: Growth and increased profitability driven by customer satisfaction
News Preview
LINKÖPING, Sweden, Dec. 12, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) reported high order bookings, increased sales and profitability in the first half of 25/26. High levels of customer satisfaction resulted in new and expanded customer commitments, helping to further strengthen Sectra's m...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
GMAB
LISTED
CPH
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CELC
LISTED
NASDAQ
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
News Preview
MINNEAPOLIS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated results from the randomized, Phase 3 VIKTORIA-1 trial for gedatolisib, a multi-target PI3K/AKT/mTOR (“PAM”) inhibitor, in adults with hormone receptor...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D
News Preview
STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy SVF-001, targeting hepatitis B and D, as a late-breaking abstract at the HepDart scientific meeting held December 7-11 in Honolulu, Hawaii. The results are...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
1SXP
LISTED
XETR
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
News Preview
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
Währungsbereinigtes Umsatzwachstum von 5,8 % auf 986,2 Mio. EUR
Währungsbereinigte EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %)
Anteil margenstarker High Value Solutions (HVS) bei 57 % (Vorjahr: 55 %)
Prognose für 2026: Währungsbereinigtes Umsatzwachstum von 2–5 % und EBITDA-M......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
AFX
LISTED
XETR
Carl Zeiss Meditec schließt das Geschäftsjahr 2024/25 mit solidem Umsatzwachstum und einem leichten Anstieg des EBITA ab
News Preview
Carl Zeiss Meditec schließt das Geschäftsjahr 2024/25 mit solidem Umsatzwachstum und einem leichten Anstieg des EBITA[1] ab
Umsatzwachstum bei Geräten und Verbrauchsmaterialien sowie stärkere Auftragseingänge und Auftragsbestände zum Jahresende
JENA, 11. Dezember 2025
Carl Zeiss Meditec erreichte im Geschäftsjahr 2024/25 einen Umsatz v......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
1SXP
LISTED
XETR
SCHOTT Pharma delivers on full-year revenue and profitability targets
News Preview
SCHOTT Pharma delivers on full-year revenue and profitability targets
Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies
EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%)
Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%)
Guidance for FY 2026: 2-5% rev......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
AFX
LISTED
XETR
Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA
News Preview
Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA[1]
Growth in both equipment and consumables sales, along with stronger order intake and higher order backlogs at year-end
JENA, 11 December 2025
Carl Zeiss Meditec achieved revenue of EUR 2,228 million in fiscal year 2024/25 (prior year:......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
GMAB
LISTED
CPH
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ZEAL
LISTED
CPH
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
News Preview
Press release – No. 19 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ZEAL
LISTED
CPH
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
News Preview
Press release – No. 18 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
IBAB
LISTED
EURONEXT
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity
News Preview
Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
GNFT
LISTED
EURONEXT
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today reports encouraging preliminary Phase 1b data from its CCA clinical trial evaluating GNS561 in comb...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
EAPI
LISTED
EURONEXT
Tristan Imbert co-opted as Independent Director
News Preview
Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to t...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
ERF
LISTED
EURONEXT
The Eurofins Consumer Product Testing Network Completes Significant Laboratory Expansion in Vietnam
News Preview
Eurofins Consumer Product Testing Vietnam has completed a major expansion, seeing the laboratory move to a purpose-built 7,000 sq. m laboratory in Ho Chi Minh City. This new facility provides more than two and a half times the floor space of Eurofins Consumer Product Testing Vietnam’s previous site. This investment strengthens the Eurofins Consume...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a clinical study of sevuparin as a potential new treatment for chronic kidney disease with anemia. The study is conducted in Italy and will evaluate the saf...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a clinical trial GOAL-HF1, evaluating the drug candidate AC01 in patients with heart failure and reduced ejection fraction (HFrEF). The study met its prima...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
AMRX
LISTED
NASDAQ
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
News Preview
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical t...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS9 December 2025 at 17.30 EET ...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CTXR
LISTED
NASDAQ
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
News Preview
Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)CRANFORD, N.J., Dec. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasd...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
TEM
LISTED
NASDAQ
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas.
“This...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TFX
LISTED
NYSE
Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
News Preview
Board of Directors authorizes new $1 billion share repurchase program Board of Directors authorizes new $1 billion share repurchase program...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
SLP
LISTED
NASDAQ
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidanc...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ICLR
LISTED
NASDAQ
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2025
FYB
LISTED
XETR
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
News Preview
Presse Release // December 09, 2025
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful lau......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2025
FYB
LISTED
XETR
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda® (Pembrolizumab), in den USA und Kanada
News Preview
Pressemitteilung // 09. Dezember 2025
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda® (Pembrolizumab), in den USA und Kanada
Lizenzpartner Zydus verfügt über umfangreiche kommerzielle Erfahrung und vermarktet mehr als 225 von der FDA zugelassene Medikamente – eine starke Ausgangsbasi......
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
FYB
LISTED
XETR
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
News Preview
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB2...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
News Preview
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
BIOA B
LISTED
STO
Leqembi included in China's commercial insurance innovative drug list
News Preview
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
BIOA B
LISTED
STO
Leqembi included in China's commercial insurance innovative drug list
News Preview
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
HIK
LISTED
LSE
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
News Preview
Ready-to-use sepsis therapy marks new advancement in time-critical treatmentLONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin i...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GMAB
LISTED
CPH
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
News Preview
Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TR...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - von First Berlin Equity Research GmbH
08.12.2025 / 15:50 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
AFX
LISTED
XETR
Beendigung der Vorstandstätigkeit von Maximilian Foerst zum 31.12.2025 und interimistische Übernahme des Vorstandsvorsitzes durch Andreas Pecher zum 01.01.2026
News Preview
Beendigung der Vorstandstätigkeit von Maximilian Foerst zum 31.12.2025 und interimistische Übernahme des Vorstandsvorsitzes durch Andreas Pecher zum 01.01.2026 – interimistische Übernahme des Aufsichtsratsvorsitzes durch Peter Kameritsch
Jena, 08. Dezember 2025
Der Aufsichtsrat der Carl Zeiss Meditec AG (ISIN: DE0005313704) und Maximilia......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
AFX
LISTED
XETR
Termination of Maximilian Foerst’s Executive Board mandate as of 31 December 2025 and interim assumption of the CEO role by Andreas Pecher as of 1 January 2026
News Preview
Termination of Maximilian Foerst’s Executive Board mandate as of 31 December 2025 and interim assumption of the CEO role by Andreas Pecher as of 1 January 2026 –
interim assumption of the Chairmanship of the Supervisory Board by Peter Kameritsch
Jena, 8 December 2025
The Supervisory Board of Carl Zeiss Meditec AG (ISIN: DE0005313704) ......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
News Preview
Preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients was presented at ASH 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in dri...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driv...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving gro...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
UCB
LISTED
EURONEXT
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
News Preview
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1Holistic Improvement: two of the three key secondary endpoints showed significantly greater number of patients demonstrated ≥50% reduction in CMSF from basel...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
KPTI
LISTED
NASDAQ
Karyopharm to Participate in Baird's Biotech Discovery Series
News Preview
NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified a...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
RXRX
LISTED
NASDAQ
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
News Preview
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP)....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
